ALL THE SMOKE PRODUCTIONS ANNOUNCES LEADERSHIP TEAM: NBA CHAMPION MATT BARNES NAMED CEO AND CO-FOUNDER, BRIAN DAILEY NAMED PRESIDENT AND COO
ALL THE SMOKE PRODUCTIONS was founded in 2024 following the closure of Showtime Sports, the television network division that helped launch the sports and culture-shaping digital series ALL THE SMOKE WITH MATT BARNES AND STEPHEN JACKSON in 2019. The ATSP ethos stems from its flagship series, focusing on unfiltered, authentic storytelling led by athletes themselves.
"We founded ALL THE SMOKE PRODUCTIONS to change the game and that is what we are doing," said Barnes. "We are telling authentic stories that matter, and it's been an incredible journey to see the impact we've had in such a short time. Year two of this company is about expanding that vision and creating more opportunities for athletes to have a voice in how their stories are told."
"The world of sports media is rapidly evolving," said Dailey, "and ALL THE SMOKE PRODUCTIONS is at the forefront of that transformation. We're not just creating compelling, important content—podcasts, series, documentaries and brands—we are leading a movement to amplify varied and diverse voices, inspire audiences and engage fans on a deeper level."
In 2024, the company made significant strides to quickly re-establish infrastructure, launch new intellectual property and continue to grow its already sizable digital audience. It also launched a new content division, ALL THE SMOKE FIGHT, bringing its total digital reach to over 20 million. The company signed Boxing Hall of Fame inductees Andre Ward and Roy Jones Jr., to key roles and established a progressive distribution strategy across social platforms, YouTube, and all major podcast outlets. New deals are pending with major OTT and streaming services.
Additionally, ALL THE SMOKE expanded its brand with a coffee table book from Simon & Schuster, a new premium Mezcal, a limited-edition sneaker collaboration, and a premium merchandise line. The company partnered with Live Nation to launch a live series, Smoke Tour Live, strengthened its alliance with online sports betting leader DraftKings, audio giant iHeartRadio and formed strategic partnerships with Meadowlark Media and Kevin Durant's Boardroom brand.
Today, just one year after its founding, ALL THE SMOKE PRODUCTIONS produces more than eight regularly scheduled premium digital series at the intersection of sports and culture, including ALL THE SMOKE, UNPLUGGED, THE ART OF WARD, MORNING KOMBAT and, in conjunction with Kevin Garnett's Content Cartel, KG: CERTIFIED and TICKET & THE TRUTH. Additional series along with multiple documentary film projects are currently in development to be announced this year.
Barnes, a member of the 2007 "We Believe" Warriors and the 2017 NBA Champion Warriors, transitioned into media following his 14-year NBA career. Along with fellow Champion and friend Stephen Jackson, Barnes founded ALL THE SMOKE in 2019, and the series quickly gained success, earning multiple awards and industry accolades, including the 2024 NAACP Image Awards, 2023 Webby Awards, and the 2021 iHeart Radio Podcast Awards.
Dailey served as Senior Vice President of Sports Programming and Strategy at Showtime Networks from 2019 until the department's closure. His leadership played a key role in transforming Showtime Sports into a leader in innovative, culturally relevant sports content and distribution. Dailey's connections with athletes, artists, and creative brands set new standards in collaborative promotion and fan engagement. He has produced several unscripted sports films and series for both linear and digital distribution. Prior to Showtime, Dailey worked at ESPN, where he developed key partnerships and pioneered broadcast integrations.
Media Contact:Chris DeBlasioE: Cdeblasio99@gmail.com
@AllTheSmokeProductions * @allthesmokeprod * @allthesmoke.productions@allthesmokeproductions * www.allthesmokeproductions.com All The Smoke Productions
View original content to download multimedia:https://www.prnewswire.com/news-releases/all-the-smoke-productions-announces-leadership-team-nba-champion-matt-barnes-named-ceo-and-co-founder-brian-dailey-named-president-and-coo-302373853.html
SOURCE ALL THE SMOKE PRODUCTIONS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
a day ago
- USA Today
Boston Celtics jersey history No. 27 - Marvin Barnes (1978-79)
The Boston Celtics have had players suiting up in a total of 68 different jersey numbers (and have three others not part of any numerical series) since their founding at the dawn of the Basketball Association of America (BAA -- the league that would become today's NBA), worn by well over 500 players in the course of Celtics history. To commemorate the players who wore those numbers, Celtics Wire is covering the entire history of jersey numbers and the players who sported them since the founding of the team. With 25 of those jerseys now retired to honor some of the greatest Celtics to wear those jerseys, there is a lot of history to cover. And for today's article, we will continue with the sixth of 13 people to wear the No. 27, Boston big man alum Marvin Barnes. After ending his college career at Providence, Barnes was picked up with the second overall selection of the 1974 NBA Draft by the Philadelphia 76ers. The Providence, Rhode Island native would play the first two seasons of his pro career with the ABA's (defunct) Spirits of St. Louis instead. He also played for the Detroit Pistons and (then) Buffalo Braves (now, Boston Celtics - it's a long story) before he was dealt to Boston in 1978. His stay with the team would span just 38 games before he would be cut. During his time suiting up for the Celtics, Barnes wore only jersey No. 27 and put up 8.1 points, 4.7 rebounds, 1.4 assists, and 1.0 steals and blocks per game. All stats and data courtesy of Basketball Reference.
Yahoo
2 days ago
- Yahoo
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. Viatris Chief R&D Officer Philippe Martin said, "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study. Thank you to the patients and investigators who contributed to the trial." The Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions. In June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. The Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. About the MR-139 3001 Phase 3 StudyThe MR-139 3001 Phase 3 trial consisted of a randomized, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks. For more information on the MR-139 study design, refer to (NCT06400511). About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking StatementsThis press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing; given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study; the Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions; in June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions; and the Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. View original content to download multimedia: SOURCE Viatris Inc. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
PR Newswire Empowers Brands for AI Search and Strategic Communications with Multichannel Content Amplification
Key features for optimizing content in an AI-driven search environment NEW YORK, July 18, 2025 /PRNewswire/ -- As Large Language Models (LLMs) rapidly transform the search landscape, PR Newswire is empowering communicators to excel through its advanced Multichannel Amplification™ services. PR Newswire helps organizations publish once and reach everywhere, enhancing topical authority and shaping favorable AI-generated summaries. Key Features of PR Newswire's Multichannel Amplification services: Topical Authority: Build and reinforce your brand's presence in authoritative search results by leveraging PR Newswire's industry-leading distribution network, designed to surface expert-driven content across major search engines and media outlets. This is crucial for establishing your brand as a trusted source in an LLM-driven search environment. AI-Friendly Optimization: Structure and distribute press releases that are easily understood and surfaced by AI models, including LLMs. This boosts your brand's visibility and positioning in AI-generated answers and summaries, ensuring your message is accurately interpreted and presented in the evolving search ecosystem. One Message, Multiple Missions: Whether it's media relations, investor updates, brand awareness, or thought leadership, PR Newswire enables you to fulfill multiple communications objectives through a single, strategically crafted piece of content, optimized for how LLMs process information. "PR Newswire's platform is built for today's evolving media landscape, deeply impacted by the rise of LLMs," said Jeff Hicks, Chief Product and Technology Officer at PR Newswire. "We're not just distributing press releases – we're giving brands the tools to influence conversations, rank as topical authorities, and be found in the ways people are searching today, which increasingly means through LLM-powered interfaces." Helpful resources Ready to enhance your brand's visibility in the age of AI? Learn more about PR Newswire's Multichannel Amplification services: Watch PR Newswire's recent on-demand webinar, "From Keywords to Conversations: How AI Search is Reshaping PR," to explore how smart distribution can maximize visibility in the age of AI and LLMs: About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at View original content to download multimedia: SOURCE PR Newswire
